Cite
HARVARD Citation
Awada, G. et al. (2022). A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Melanoma research. 32 (3), pp. 183-191. [Online].